ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio0.79
Current Ratio10.65
Quick Ratio8.88
Price-To-Earnings
Trailing P/E Ratio-3.20
Forward P/E Ratio-4.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales12.45
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book6.87
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-119.34%
Return on Equity-89.78%
Return on Assets-29.51%
Miscellaneous
Employees295
Outstanding Shares46,350,000
Market Cap$285.05 million
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.03. The biotechnology company earned $4.66 million during the quarter, compared to analyst estimates of $5.35 million. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
5 equities research analysts have issued 1 year price objectives for ADMA Biologics' shares. Their forecasts range from $5.00 to $13.00. On average, they expect ADMA Biologics' stock price to reach $9.50 in the next year. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Adaptimmune Therapeutics (ADAP), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), Acorda Therapeutics (ACOR), Heska (HSKA), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Nightstar Therapeutics (NITE), Mesoblast (MESO), Novavax (NVAX), Scholar Rock (SRRK), Vericel (VCEL), Voyager Therapeutics (VYGR), Replimune Group (REPL) and La Jolla Pharmaceutical (LJPC).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.14%), 683 Capital Management LLC (1.91%), Stonepine Capital Management LLC (1.84%), Millennium Management LLC (0.51%), Northern Trust Corp (0.45%) and Ardsley Advisory Partners (0.18%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which major investors are selling ADMA Biologics stock?
Which major investors are buying ADMA Biologics stock?
ADMA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Stonepine Capital Management LLC, Northern Trust Corp, 683 Capital Management LLC, Ardsley Advisory Partners, Private Advisor Group LLC, Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $6.1150.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $285.05 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
